Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT3789, a selective degrader of SMARCA2 protein for the treatment of advanced or metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion; PRT7732, a selective and orally bioavailable SMARCA2 degraders to treat advanced or metastatic solid tumors; and PRT2527, a cyclin-dependent kinase 9 inhibitor for the treatment of advanced solid tumors. The company’s CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC, and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
Pipeline Progress | Explore Prelude's advancing clinical trials, including PRT3789's promising results in upper GI tumors and PRT7732's rapid Phase 1 progression |
Financial Health | With $103.1M cash and no debt, Prelude maintains a strong balance sheet, though careful cash management remains crucial amid ongoing R&D expenses |
Competitive Edge | Delve into Prelude's novel approach to cancer treatment through targeted degraders, facing competition from pharma giants like Pfize |
Future Catalysts | Analyst targets range from $1 to $7, with key data readouts for PRT3789 and PRT7732 expected in H2 2025, potentially reshaping Prelude's market position |
Metrics to compare | PRLD | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPRLDPeersSector | |
---|---|---|---|---|
P/E Ratio | −0.8x | −6.8x | −0.7x | |
PEG Ratio | −0.09 | 0.12 | 0.00 | |
Price/Book | 1.3x | 0.9x | 2.6x | |
Price / LTM Sales | 13.7x | 13.0x | 3.4x | |
Upside (Analyst Target) | 217.5% | 272.8% | 38.0% | |
Fair Value Upside | Unlock | 6.3% | 5.2% | Unlock |